These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 26956626)

  • 1. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
    Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S
    J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer.
    Uddin S; Ahmed M; Hussain AR; Jehan Z; Al-Dayel F; Munkarah A; Bavi P; Al-Kuraya KS
    Lab Invest; 2009 Oct; 89(10):1115-27. PubMed ID: 19636294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
    Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
    Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
    Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
    Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells.
    Hussain AR; Ahmed M; Ahmed SO; Al-Thari S; Khan AS; Razack S; Platanias LC; Al-Kuraya KS; Uddin S
    Leuk Lymphoma; 2009 Jul; 50(7):1204-13. PubMed ID: 19557642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS; Liu DS; Dai CW; Li RJ
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
    Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M
    Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia.
    Wang Q; Zhou HS; Huang KK; Jiang XJ; Wu FQ; Cao R; Yin CX; Liao LB; Zheng ZX; He H; Lin R; Yi ZS; Xu D; Yang M; Meng FY
    Int J Oncol; 2012 Feb; 40(2):418-26. PubMed ID: 22002244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl.
    Mc Gee MM; Campiani G; Ramunno A; Fattorusso C; Nacci V; Lawler M; Williams DC; Zisterer DM
    J Pharmacol Exp Ther; 2001 Jan; 296(1):31-40. PubMed ID: 11123359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
    Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
    Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
    Piedfer M; Bouchet S; Tang R; Billard C; Dauzonne D; Bauvois B
    Biochim Biophys Acta; 2013 Jun; 1833(6):1316-28. PubMed ID: 23481040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting SKP2/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation.
    Liu Y; Shao Z; Liao Y; Xia X; Huang C; He J; Hu T; Yu C; Jiang L; Liu J; Huang H
    Eur J Pharmacol; 2020 Sep; 883():173366. PubMed ID: 32679184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.
    Li QF; Yan J; Zhang K; Yang YF; Xiao FJ; Wu CT; Wang H; Wang LS
    Biochem Biophys Res Commun; 2011 Feb; 405(1):31-6. PubMed ID: 21195056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells.
    Nakamura S; Takemura T; Tan L; Nagata Y; Yokota D; Hirano I; Shigeno K; Shibata K; Fujie M; Fujisawa S; Ohnishi K
    Carcinogenesis; 2011 Dec; 32(12):1758-72. PubMed ID: 21890458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of SKP2 in Papillary Thyroid Cancer Acts Synergistically With TRAIL on Inducing Apoptosis via ROS.
    Pratheeshkumar P; Siraj AK; Divya SP; Parvathareddy SK; Begum R; Melosantos R; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1530-1544. PubMed ID: 29300929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
    Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
    Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model.
    Nasr RR; Hmadi RA; El-Eit RM; Iskandarani AN; Jabbour MN; Zaatari GS; Mahon FX; Pisano CC; Darwiche ND
    Int J Cancer; 2015 Aug; 137(3):698-709. PubMed ID: 25557649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGCG stabilizes p27kip1 in E2-stimulated MCF-7 cells through down-regulation of the Skp2 protein.
    Huang HC; Way TD; Lin CL; Lin JK
    Endocrinology; 2008 Dec; 149(12):5972-83. PubMed ID: 18719023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells.
    Engür S; Dikmen M; Öztürk Y
    Immunopharmacol Immunotoxicol; 2016; 38(2):87-97. PubMed ID: 26667773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
    Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.